Browse ITGAE

Summary
SymbolITGAE
Nameintegrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location17p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF01839 FG-GAP repeat
PF00357 Integrin alpha cytoplasmic region
PF08441 Integrin alpha
PF00092 von Willebrand factor type A domain
Function

Integrin alpha-E/beta-7 is a receptor for E-cadherin. It mediates adhesion of intra-epithelial T-lymphocytes to epithelial cell monolayers.

> Gene Ontology
 
Biological Process GO:0007229 integrin-mediated signaling pathway
GO:0030198 extracellular matrix organization
GO:0043062 extracellular structure organization
Molecular Function -
Cellular Component GO:0008305 integrin complex
GO:0009897 external side of plasma membrane
GO:0043235 receptor complex
GO:0098552 side of membrane
GO:0098636 protein complex involved in cell adhesion
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-1474244: Extracellular matrix organization
R-HSA-216083: Integrin cell surface interactions
Summary
SymbolITGAE
Nameintegrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location17p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ITGAE and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ITGAE and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26921343Lung CarcinomaPromote immunity (infiltration, T cell function)Here, we used viable human lung tumor slices and autologous tumor antigen-specific T-lymphocyte clones to provide evidence that CD103 is directly involved in T-lymphocyte recruitment within epithelial tumor islets and intratumoral early T-cell signaling. Mechanistic investigations revealed that TGFβ bound to its receptors (TGFBR), which promoted the recruitment and phosphorylation of integrin-linked kinase (ILK) by TGFBR1. We further show that ILK interacted with the CD103 intracellular domain, resulting in protein kinase B (PKB)/AKT activation, thereby initiating integrin inside-out signaling.
27267849Breast carcinomaPromote immunity (T cell function)CD8 status showed similar but less significant associations, but the combination of dual CD103+CD8+?TIL status was the most strongly prognostic combination for relapse-free and overall survival (HR = 0.10; 95% CI, 0.07-0.62; P = 0.006 and HR = 0.09; 95% CI, 0.07-0.57; P = 0.003, respectively). CD103 TILs are indicative of a good prognosis specifically within the basal-like subtype of breast cancer.
23188505Epithelial tumorPromote immunity (T cell function)Flow-based adhesion assay showed that engagement of CD103 or LFA-1, together with TCR, enhances the strength of the T-cell/target cell interaction.
28486109MelanomaPromote immunity (T cell function)Our data indicate that lack of CD103+DCs within the tumor microenvironment dominantly resists the effector phase of an anti-tumor T?cell response, contributing to immune escape.
21207371Colon CarcinomaInhibit immunity (T cell function)Here we show that CD103, an integrin mediating lymphocyte retention in epithelial tissues, is expressed at high levels on tumor-infiltrating FoxP3+ Treg in several types of murine cancer. In the CT26 model of colon cancer up to 90% of the intratumoral FoxP3+ cells expressed CD103 compared to less than 20% in lymphoid organs. CD103+ Treg suppressed T effector cell activation more strongly than CD103(neg) Treg.
28628092Lung CarcinomaPromote immunityTumors with a high density of CTLs showed enrichment for transcripts linked to tissue-resident memory cells (TRMcells), such as CD103, and CTLs from CD103hi tumors displayed features of enhanced cytotoxicity.
24190978Ovarian CarcinomaPromote immunity (T cell function)Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Tumors containing CD8(+) TILs that were CD103(-) showed poor prognosis equivalent to tumors lacking CD8(+) TILs altogether. CD103(+) TILs comprise intraepithelial, activated CD8(+) T cells, and NK cells and are strongly associated with patient survival in HGSC.
Summary
SymbolITGAE
Nameintegrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location17p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ITGAE in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolITGAE
Nameintegrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location17p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ITGAE in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.010.971
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3380.668
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2630.676
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5120.164
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.690.655
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2890.883
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2140.46
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0390.973
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4160.743
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0720.964
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1680.945
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4040.00093
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ITGAE in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolITGAE
Nameintegrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location17p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGAE. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolITGAE
Nameintegrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location17p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGAE. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGAE.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolITGAE
Nameintegrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location17p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGAE. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolITGAE
Nameintegrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location17p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ITGAE expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolITGAE
Nameintegrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location17p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ITGAE and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolITGAE
Nameintegrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location17p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ITGAE collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.